NZ578697A - Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof - Google Patents

Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Info

Publication number
NZ578697A
NZ578697A NZ578697A NZ57869708A NZ578697A NZ 578697 A NZ578697 A NZ 578697A NZ 578697 A NZ578697 A NZ 578697A NZ 57869708 A NZ57869708 A NZ 57869708A NZ 578697 A NZ578697 A NZ 578697A
Authority
NZ
New Zealand
Prior art keywords
polymorphs
compositions
manufacture
methods
macrocyclic
Prior art date
Application number
NZ578697A
Other languages
English (en)
Inventor
Yu-Hung Chiu
Tessie Mary Che
Alex Romero
Yoshi Ichikawa
Youe-Kong Shue
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ578697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Priority to NZ601347A priority Critical patent/NZ601347A/xx
Publication of NZ578697A publication Critical patent/NZ578697A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ578697A 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof NZ578697A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601347A NZ601347A (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
NZ578697A true NZ578697A (en) 2012-08-31

Family

ID=38661942

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ578697A NZ578697A (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
NZ601347A NZ601347A (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601347A NZ601347A (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Country Status (23)

Country Link
US (5) US7378508B2 (enExample)
EP (3) EP2125850B1 (enExample)
JP (2) JP5468388B2 (enExample)
KR (2) KR20090117924A (enExample)
CN (2) CN102746353A (enExample)
BR (1) BRPI0806878A2 (enExample)
CA (2) CA2880860A1 (enExample)
CY (1) CY1120358T1 (enExample)
DK (1) DK2125850T3 (enExample)
ES (2) ES2821384T3 (enExample)
HR (1) HRP20180912T1 (enExample)
HU (2) HUE052444T2 (enExample)
IL (2) IL199984A0 (enExample)
LT (1) LT2125850T (enExample)
MX (2) MX348083B (enExample)
NZ (2) NZ578697A (enExample)
PL (2) PL2125850T3 (enExample)
PT (2) PT2125850T (enExample)
RU (1) RU2478643C2 (enExample)
SI (1) SI2125850T1 (enExample)
TR (1) TR201810589T4 (enExample)
TW (2) TWI425942B (enExample)
WO (1) WO2008091554A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
ATE516024T1 (de) * 2004-05-14 2011-07-15 Optimer Pharmaceuticals Inc Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
EA027622B1 (ru) * 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
BR112012029262A8 (pt) * 2010-05-18 2018-06-12 Merck Sharp & Dohme Métodos de tratamento de infecção bacteriana recorrente
WO2012106722A2 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US8722863B2 (en) * 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
KR20150001802A (ko) * 2012-05-10 2015-01-06 테바 파마슈티칼 웍스 엘티디. 피닥소마이신의 고상 형태 및 이의 제조 방법
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
AU2014224397A1 (en) 2013-03-08 2015-09-10 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
US9862740B2 (en) 2014-02-25 2018-01-09 Olon S.P.A. Process for preparing novel forms of tiacumicin B
SI3119793T1 (en) 2014-03-18 2018-06-29 Xellia Pharmaceuticals Aps NEW POLYMORPHES AND NEW SOLID CONDITIONS OF TIACUMICINE B
HRP20181756T1 (hr) 2014-05-09 2018-12-28 Astellas Pharma Europe Ltd. Režim liječenja sa spojem tiakumicina
US20150329582A1 (en) * 2014-05-13 2015-11-19 Jef DeBrabander Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
US10548912B2 (en) 2015-07-03 2020-02-04 Astellas Pharma Europe Ltd. Dosage regimen for a tiacumicin compound
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321361A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company Demycinosyltylosin and process for its production
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
KR100832145B1 (ko) 2000-04-28 2008-05-27 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
WO2006085838A1 (en) 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
ATE516024T1 (de) * 2004-05-14 2011-07-15 Optimer Pharmaceuticals Inc Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CA2626698C (en) 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
EP2468761A1 (en) 2012-06-27
PL2125850T3 (pl) 2018-08-31
TWI425942B (zh) 2014-02-11
US20070259949A1 (en) 2007-11-08
CN101663312B (zh) 2013-10-23
IL199984A0 (en) 2010-04-15
NZ601347A (en) 2013-11-29
US7863249B2 (en) 2011-01-04
CA2676061C (en) 2016-01-19
CY1120358T1 (el) 2019-07-10
JP5468388B2 (ja) 2014-04-09
CN102746353A (zh) 2012-10-24
LT2125850T (lt) 2018-08-10
EP3412678A1 (en) 2018-12-12
TW201350114A (zh) 2013-12-16
TR201810589T4 (tr) 2018-08-27
JP2013241440A (ja) 2013-12-05
HUE039395T2 (hu) 2018-12-28
MX348083B (es) 2017-05-25
EP2125850A1 (en) 2009-12-02
RU2478643C2 (ru) 2013-04-10
PT2125850T (pt) 2018-07-11
HRP20180912T1 (hr) 2018-07-27
JP2010516681A (ja) 2010-05-20
CN101663312A (zh) 2010-03-03
US8883986B2 (en) 2014-11-11
US20100081800A1 (en) 2010-04-01
EP3412678B1 (en) 2020-08-19
CA2676061A1 (en) 2008-07-31
WO2008091554A1 (en) 2008-07-31
US20080194497A1 (en) 2008-08-14
TWI453015B (zh) 2014-09-21
US20130252914A1 (en) 2013-09-26
TW200840562A (en) 2008-10-16
CA2880860A1 (en) 2008-07-31
IL220255A0 (en) 2012-07-31
JP5764168B2 (ja) 2015-08-12
US7378508B2 (en) 2008-05-27
RU2009131727A (ru) 2011-02-27
HUE052444T2 (hu) 2021-05-28
EP2125850B1 (en) 2018-05-30
PL3412678T3 (pl) 2020-12-14
PT3412678T (pt) 2020-09-29
ES2676308T3 (es) 2018-07-18
SI2125850T1 (en) 2018-08-31
KR20150006082A (ko) 2015-01-15
US8859510B2 (en) 2014-10-14
KR20090117924A (ko) 2009-11-16
AU2008209580A1 (en) 2008-07-31
MX2009007730A (es) 2009-08-07
US20090163428A1 (en) 2009-06-25
ES2821384T3 (es) 2021-04-26
BRPI0806878A2 (pt) 2014-06-24
DK2125850T3 (en) 2018-07-30

Similar Documents

Publication Publication Date Title
NZ578697A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
MY156254A (en) Salts and polymorphs of a tetracycline compound
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
MX2009014104A (es) Metodos para sintetizar cinacalcet y sales del mismo.
UA94833C2 (en) Substituted bicyclolactams
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
WO2009004427A3 (en) Benzimidazole derivatives
UA101912C2 (en) Fungicidal composition
TW200716558A (en) Heteroaroyl-substituted serineamides
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
TN2012000248A1 (en) Novel spiropiperidine compounds
TW200716519A (en) Benzoyl-substituted serineamides
WO2011073112A3 (en) Mannose derivatives as antagonists of bacterial adhesion
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
NZ593892A (en) Antibiotic compositions for the treatment of gram negative infections
MX2009004096A (es) Metabolitos de talarozol.
NZ598165A (en) Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
WO2007143507A3 (en) Preparation and utility of substituted erythromycin analogs
UA101490C2 (ru) Ингибиторы передачи сигналов брасиностероидов
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
WO2007069020A3 (en) N-hydroxyamide derivatives possessing antibacterial activity
MY156304A (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JAN 2015 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20130404

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2016 BY COMPUTER PACKAGES INC

Effective date: 20141231

ASS Change of ownership

Owner name: MERCK SHARP + DOHME CORP., US

Effective date: 20151029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2017 BY THOMSON REUTERS

Effective date: 20151213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2018 BY THOMSON REUTERS

Effective date: 20161214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2019 BY THOMSON REUTERS

Effective date: 20171214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2020 BY THOMSON REUTERS

Effective date: 20181220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2021 BY THOMSON REUTERS

Effective date: 20191217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2022 BY THOMSON REUTERS

Effective date: 20201215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2023 BY THOMSON REUTERS

Effective date: 20211207

ASS Change of ownership

Owner name: MERCK SHARP + DOHME LLC, US

Effective date: 20220922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2024 BY THOMSON REUTERS

Effective date: 20221206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2025 BY THOMSON REUTERS

Effective date: 20231205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2026 BY THOMSON REUTERS

Effective date: 20241206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2027 BY THOMSON REUTERS

Effective date: 20251205